While Summit’s Harmoni-6 results drew a mixed reaction, Eli Lilly’s positive Retvemo data was expanded its potential in adjuvant NSCLC.

AbbVie has received approval from the EC for Aquipta, an oral CGRP receptor antagonist, for the acute treatment of migraine in adults, with or without aura.

Eli Lilly and Company has entered into a licensing agreement worth up to $1.26bn with Hanmi Pharm to develop, manufacture and commercialise Hanmi’s biologic drug candidate, sonefpeglutide, worldwide ...

Contraline could become the first to commercialise a reversible male contraceptive drug, provided the treatment is successful in Phase III.

At ASCO 2026, oral abstract presenters highlighted new and exciting central nervous system (CNS) tumour treatments.

AstraZeneca has secured FDA approval for Imfinzi in combination with BCG induction and maintenance therapy for adults with BCG-naïve, high-risk NMIBC.

As the first-to-market DPP-1 inhibitor in the respiratory field, Brinsupri is on course to become the standard of care in bronchiectasis treatment.

At ASCO 2026, companies debuted data that could hold the potential to disrupt the frontline treatment paradigm for various subtypes of NSCLC.

The field is ecstatic about the prospect of a targeted therapy meaningfully extending overall survival in pancreatic cancer.

The FDA has accepted BMS' sNDA for Camzyos to treat adolescents aged 12 to under 18 years with symptomatic oHCM.

Japan’s pharmaceutical sector is gradually reorienting from deep, validation-led development towards execution-driven partnerships, as global pressure compresses timelines across drug development.

At ASCO 2026, Pfizer presented top line data for the Phase III TALAPRO-3 clinical trial, evaluating Talzenna combined with Xtandi.